XML 207 R163.htm IDEA: XBRL DOCUMENT
v3.22.4

Liabilities related to business combinations and to non-controlling interests - Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests (Details) - EUR (€) € in Millions | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
--- | --- | --- | ---
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items] |  |  |
Commitments relating to contingent consideration in connection with business combinations | € 604 | € 689 | € 1,043
Less than 1 year |  |  |
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items] |  |  |
Commitments relating to contingent consideration in connection with business combinations | 104 |  |
From 1 to 3 years |  |  |
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items] |  |  |
Commitments relating to contingent consideration in connection with business combinations | 145 |  |
From 3 to 5 years |  |  |
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items] |  |  |
Commitments relating to contingent consideration in connection with business combinations | 0 |  |
More than 5 years |  |  |
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items] |  |  |
Commitments relating to contingent consideration in connection with business combinations | 355 |  |
Bayer contingent consideration |  |  |
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items] |  |  |
Commitments relating to contingent consideration in connection with business combinations Bayer | 400 |  |
MSD contingent consideration (European vaccines business) |  |  |
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items] |  |  |
Commitments relating to contingent consideration in connection with business combinations MSD | € 200 |  |

X
- Definition Commitments Relating To Contingent Consideration In Connection With Business Combinations + References No definition available. + Details
Name: | sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments relating to contingent consideration in connection with business combinations bayer. + References No definition available. + Details
Name: | sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinationsBayer
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Relating To Contingent Consideration In Connection With Business Combinations MSD + References No definition available. + Details
Name: | sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinationsMSD
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items] + References No definition available. + Details
Name: | sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_BayerScheringPharmaAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |